查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球抗菌药物敏感性测试市场-2022-2029
市场调查报告书
商品编码
1146441

全球抗菌药物敏感性测试市场-2022-2029

Global Antimicrobial Susceptibility Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），全球抗菌药物敏感性测试市场规模预计将以 5.4% 的复合年增长率增长。

抗菌药物敏感性测试 (AST) 是一种实验室技术，医学和临床实验室技术人员使用该技术来确定哪些抗生素治疗方案对个体患者最有效。它还用于评估医院、诊所和国家传染病控制和预防计划的治疗服务。

市场动态

技术进步、传染病流行、政府和私人组织增加研发资金以及医疗保健基础设施的进步推动了全球抗菌药物敏感性测试市场的增长。

全球对抗菌药物敏感性测试的需求不断增长，正在推动市场增长

抗菌素耐药性 (AMR) 已成为全球公共卫生的主要威胁。根据世界卫生组织 (WHO) 的数据，世界所有地区的抗生素耐药性已经上升到危险的高水平，导致发病率和死亡率上升。世界银行还估计，耐药性感染将引发全球经济危机，到 2050 年每年将有 2800 万人陷入极端贫困，每年使整个全球经济损失 1 万亿美元。我在这里。

为了控制 AMR 的发生和传播，准确、及时地检测抗菌药物耐药性并在抗菌药物管理的基础上实施适当的抗菌治疗非常重要。细菌感染的最佳治疗依赖于 AST 结果，这是每个临床微生物实验室日常工作的一部分。本报告将提供对区域抗菌药物敏感性模式的了解，并帮助医疗保健专业人员选择最有效的抗菌治疗方法。例如，如果一种药物的 AMR 率大于 20%，则不应单独使用该药物作为治疗感染的经验性疗法。

此外，市场参与者正在采用收购和产品发布等市场策略。例如，2022 年 4 月，BIOMERIEUX 同意收购 Specific Diagnostics。这家美国私人控股公司是 SPECIFIC REVEAL Rapid AST 系统的开发商，该系统是一种快速抗菌药敏试验 (AST)，可直接从阳性血培养中提供表型 AST。此外，2020 年 2 月，Bio-Rad Laboratories, Inc. 收购了诊断产品开发商和製造商 Exact Diagnostics, Inc.，以确保测试结果的有效性和一致性。对 Exact Diagnostics 的收购使 Bio-Rad Laboratories, Inc. 可以获得移植、呼吸系统、病毒学、微生物学、性传播疾病和病媒传播疾病领域的分子质量控制产品的综合目录。

抗菌药敏测试产品/设备的弱点阻碍市场增长

但是，除了成本高之外，分子生物学方法的主要缺点是只能通过可用的探针检测靶向抗性基因，而且抗性基因不一定与抗性表型的表达相关，不要高估你的耐受性。此外，自动化和半自动化系统具有固有的优势和局限性，抗生素、软件版本和卡片之间的结果可能会有很大差异。因此，某些系统可能无法正确分类特定药物的敏感性特征，从而导致敏感性类别的错误分类。似乎低接种量会极大地影响这些系统的结果，导致错误地报告易感性。

COVID-19 影响分析

COVID-19 大流行影响了 AMR 的监测、预防和控制，因为与 AMR 的合作有限、资金减少以及护理、医疗和公共卫生人员的利用率不足。稻田。根据临床实验室标准协会 (CLSI) 2020 年报告，需要快速诊断来确定患者是否患有传染病，确定病毒或细菌感染的来源，并确定病因及其易感性特征，非常需要。通过快速识别可疑病原体并确定其对治疗的敏感性，实验室可以在快节奏的环境中指导适当的一线临床决策。这不仅大大改善了个体的预后，而且避免了不必要的抗生素使用。此外，增加使用洗手液和表面清洁剂等消毒剂预计将在未来几年增加具有抗菌素耐药性的病原微生物的比例。

细分分析

在预测期内（2022-2029 年），自动化实验室设备领域预计将以最快的复合年增长率增长

自动化实验室设备市场份额最大。根据 2022 年发表在《抗生素杂誌》上的一篇文章，目前用于快速 AST 的技术包括市场上基于微量稀释敏感性测试的自动化和半自动化仪器。例如，Phoenix System 被临床微生物实验室广泛接受并用于鑑定和抗菌药敏试验。它使用氧化还原指示剂（阿拉玛蓝和刃天青染料），并采用在各种浓度的抗菌剂存在下通过检测细菌生长来确定易感性的原理。 Microscan Walkaway Plus 系统还为各种革兰氏阳性和革兰氏阴性需氧菌提供准确、快速的鑑定和药敏结果。

此外，AutoSCAN-3 可用作第一代 Microscan 无人值守系统。新版本的 Auto-ACAN-4 和 AutoSCAN-WalkAway 仪器已经过改进，并使用不需要冷藏的干燥面板。 AutoSCAN-WalkAway 是一种检测细菌□活性的系统，可以同时处理 96 个面板。 AST 先进自动化系统的出现刺激了全球市场。

区域分析

北美在全球抗菌药物敏感性测试市场中占有最大的市场份额。

北美在抗菌药物敏感性测试市场中占主导地位，预计在预测期内将呈现类似趋势。北美抗菌药物敏感性测试市场的增长归因于技术进步、传染病数量的增加、产品推出的增加以及主要参与者的存在。

根据 bioMerieux 组织的数据，美国每年发生超过 280 万例抗生素耐药性感染。耐药菌的出现是一种不可预知的现象，由于抗生素使用不当而加剧和加速。该地区不断增加的抗菌药物敏感性测试正在推动市场。

此外，市场参与者正在采用收购和产品发布等市场策略。例如，2022年5月，Accelerate Diagnostics宣布新产品“Accelerate Arc Module”和“BC Kit”的商业化。 Accelerate Arc Module 和 BC 试剂盒是在线离心和自动化样品製备技术的一种新应用，与血液培养试剂盒一起，可提供可直接转移到 MALDI 点样板上的经过洗涤的微生物细胞悬浮液。此外，Accelerate PhenoTest BC 试剂盒 AST 配置使实验室能够比当前标准方法提前几天直接报告阳性血培养的鑑定和抗菌药敏试验结果。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 感染增加
      • 技术进步
    • 限制因素
    • 严格的规定
    • 商机
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 手动抗菌药敏试验产品
    • 药敏试验盘
    • MIC 条
    • 灵敏度测试板
  • 自动检测设备
  • 消耗品

第 8 章方法

  • 肉汤稀释法
  • 快速自动化方法
  • 圆盘扩散法
  • 梯度扩散法
  • 分子检测方法

第 9 章按测试类型

  • 抗菌
  • 抗真菌剂
  • 驱虫剂
  • 其他

第 10 章按应用程序

  • 临床诊断
  • 药物发现和开发
  • 其他

第 11 章最终用户

  • 诊断中心/医院
  • 製药和生物技术公司
  • 合同研发组织 (CRO)
  • 研究和学术机构

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 14 章公司简介

  • bio Merieux S.A.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Merck Group
  • HiMedia Laboratories
  • Alifax Holding S.p.A.
  • Creative Diagnostics
  • Synbiosis

第 15 章全球抗菌药物敏感性测试市场数据M

简介目录
Product Code: DMCD1107

Market Overview

The global antimicrobial susceptibility testing market size was growing at a CAGR of 5.4% during the forecast period (2022-2029).

Antimicrobial susceptibility testing (AST) is a laboratory technique conducted by medical technologists or clinical laboratory scientists to determine which antimicrobial regimen is particularly efficacious for individual patients. On an enormous scale, it helps evaluate treatment services delivered by hospitals, clinics, and national programs for managing and preventing infectious diseases.

Market Dynamics

The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.

The rising need for antimicrobial susceptibility testing across the globe drives the market growth

Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.

Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMERIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market

However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the limited ability to work with AMR partnerships decreased funding, and reduced availability of nursing, medical, and public health staff affected AMR surveillance, prevention, and control. According to the Clinical and Laboratory Standards Institute (CLSI) 2020 report, there is a critical need for rapid diagnostics to determine if a patient has an infection, determine viral and bacterial sources, and identify the etiologic agent and its susceptibility profile. Labs can guide the right-first-time clinical decisions in fast-paced environments by fast identifying the suspected pathogen and determining its susceptibility to treatment. Not only can this significantly improve individual outcomes, but the approach also avoids unnecessary antibiotic use. In addition, increased use of disinfectants, including hand sanitizers and surface cleaners, is anticipated to cause inflated rates of antimicrobial resistance in pathogenic microbes in the coming years.

Segment Analysis

The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.

In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market

North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.

According to the bioMerieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.

Competitive Landscape

The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMerieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.

For instance,

  • In October 2021, Thermo Fisher Scientific and Q-linea launched ASTar Technology, a quick antimicrobial susceptibility testing (AST) system that provides true minimum inhibitory concentration (MIC) data in less than 6 hours. Conventional AST techniques might take up to 72 hours to obtain findings.

bioMerieux SA

Overview:

bioMerieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.

Product Portfolio:

VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.

The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Infectious Diseases
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints:
    • 4.1.3. Strict Regulatory Procedures
    • 4.1.4. Opportunity
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Manual Antimicrobial Susceptibility Testing Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Susceptibility Testing Disks
    • 7.2.4. MIC Strips
    • 7.2.5. Susceptibility Plates
  • 7.3. Automated Laboratory Instruments
  • 7.4. Consumables

8. By Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 8.1.2. Market Attractiveness Index, By Method
  • 8.2. Broth Dilution Method*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Rapid Automated Method
  • 8.4. Disk Diffusion Method
  • 8.5. Gradient Diffusion Method
  • 8.6. Molecular Testing Method

9. By Test Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.1.2. Market Attractiveness Index, By Test Type
  • 9.2. Antibacterial*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Antifungal
  • 9.4. Antiparasitics
  • 9.5. Others

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Clinical Diagnosis*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Drug Discovery and Development
  • 10.4. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Diagnostic Centers and Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Pharmaceutical and Biotechnology Companies
  • 11.4. Contract Research Organizations (CROs)
  • 11.5. Research and Academic Institutes

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking

14. Company Profiles

  • 14.1. bioMerieux S.A.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Danaher Corporation
  • 14.3. Becton, Dickinson and Company
  • 14.4. Thermo Fisher Scientific Inc.
  • 14.5. Bio-Rad Laboratories Inc.
  • 14.6. Merck Group
  • 14.7. HiMedia Laboratories
  • 14.8. Alifax Holding S.p.A.
  • 14.9. Creative Diagnostics
  • 14.10. Synbiosis

LIST NOT EXHAUSTIVE

15. Global Antimicrobial Susceptibility Testing Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us